REPETTO, MATTEO
REPETTO, MATTEO
Universita' degli Studi di MILANO
High-performance prediction models for prostate cancer radiomics
2023 L.J. Isaksson, M. Repetto, P.E. Summers, M. Pepa, M. Zaffaroni, M.G. Vincini, G. Corrao, G.C. Mazzola, M. Rotondi, F. Bellerba, S. Raimondi, Z. Haron, S. Alessi, P. Pricolo, F.A. Mistretta, S. Luzzago, F. Cattani, G. Musi, O. De Cobelli, M. Cremonesi, R. Orecchia, D. La Torre, G. Marvaso, G. Petralia, B.A. Jereczek-Fossa
A dynamic approach to supply chain reconfiguration and ripple effect analysis in an epidemic
2023 X. Brusset, D. Ivanov, A. Jebali, D. La Torre, M. Repetto
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano
Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy
2021 M. Repetto, F. Conforti, S. Pirola, M. Calvello, L. Pala, B. Bonanni, C. Catania, G. Curigliano, T. De Pas
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies
2021 G. Antonarelli, F. Giugliano, C. Corti, M. Repetto, P. Tarantino, G. Curigliano
Precision medicine in breast cancer : From clinical trials to clinical practice
2021 E. Crimini, M. Repetto, P. Aftimos, A. Botticelli, P. Marchetti, G. Curigliano
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy
2021 L. Mazzarella, F. Giugliano, E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, E. Nicolo, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, C. Belli, C. Criscitiello, A. Esposito, M. Locatelli, I. Minchella, G. Curigliano
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021 M. Repetto, E. Crimini, F. Giugliano, S. Morganti, C. Belli, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
2021 C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. Andre, J.-. Douillard, G. Curigliano
A robust goal programming model for transfer pricing risk hedging: Preliminary results
2019 M. Repetto, D. La Torre, D. Liuzzi